Related references
Note: Only part of the references are listed.Apparent beneficial effects by nab-paclitaxel in the treatment of refractory metastatic ovarian carcinoma
Aref Agheli et al.
ANTI-CANCER DRUGS (2009)
A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer
H. Ueno et al.
BRITISH JOURNAL OF CANCER (2009)
Cancer Statistics, 2009
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer
Yoon Jae Kim et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Cancer Incidence and Incidence Rates in Japan in 2003: Based on Data from 13 Population-based Cancer Registries in the Monitoring of Cancer Incidence in Japan (MCIJ) Project
Tomohiro Matsuda et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2009)
Significantly Longer Progression-Free Survival With nab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer
William J. Gradishar et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group
Elizabeth Poplin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study
U. Pelzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer
Naiyer A. Rizvi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Serum CA19-9 Decline Compared to Radiographic Response as a Surrogate for Clinical Outcomes in Patients With Metastatic Pancreatic Cancer Receiving Chemotherapy
Derrick Wong et al.
PANCREAS (2008)
Prognostic factors in patients with gemcitabine-refractory pancreatic cancer
Kohei Nakachi et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2007)
Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation
Sunil Krishnan et al.
CANCER (2006)
Albumin-bound paclitaxel - In metastatic breast cancer
Dean M. Robinson et al.
DRUGS (2006)
CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials
NR Maisey et al.
BRITISH JOURNAL OF CANCER (2005)
Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer
AH Ko et al.
BRITISH JOURNAL OF CANCER (2005)
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer:: Results of a GERCOR and GISCAD phase III trial
C Louvet et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Pemetrexed (Alimta) in small cell lung cancer
MA Socinski
SEMINARS IN ONCOLOGY (2005)
Pancreatic Cancer Registry in Japan - 20 years of experience
S Matsuno et al.
PANCREAS (2004)
Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine
C Ziske et al.
BRITISH JOURNAL OF CANCER (2003)
Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin?
J Stemmler et al.
ONKOLOGIE (2003)
Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297
JD Berlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy
H Ueno et al.
ONCOLOGY (2000)
Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma
H Oettle et al.
ANTI-CANCER DRUGS (2000)
Share Paper
